INDP vs KPTI
INDP: A clinical-stage biotechnology company currently evaluating strategic options and potential business combinations to maximize shareholder value. KPTI: Karyopharm is a clinical-stage oncology company commercializing XPOVIO, a first-in-class XPO1 inhibitor for multiple myeloma, with ongoing trials in myelofibrosis and endometrial cancer.
Side-by-side fundamentals
| Metric | INDP | KPTI | Edge |
|---|---|---|---|
| Price as of 2026-08-06 close | $1.25 | $1.95 | |
| Market cap as of 2026-08-08 | $134M | $44M | |
| PEG as of 2026-08-08 | n/a | -0.01 | |
| Net margin as of 2026-08-08 | n/a | -129.0% | |
| Gross margin as of 2026-08-08 | n/a | +96.0% | |
| Operating margin as of 2026-08-08 | n/a | -97.0% | |
| ROE as of 2026-08-08 | -454.0% | -182.4% | KPTI higher |
| ROA as of 2026-08-08 | -299.7% | -176.9% | KPTI higher |
| Debt / equity as of 2026-08-08 | 0.00 | 3.78 | INDP lower |
| Revenue growth (YoY) as of 2026-08-08 | n/a | +6.3% | |
| Revenue CAGR (3y) SEC XBRL | n/a | -2.4% | |
| Beta as of 2026-08-08 | 1.11 | 0.97 | |
| 1-year return as of 2026-08-06 close | -82.7% | -51.6% | KPTI higher |
Fundamentals: market data, as of 2026-08-08. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-06.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.